Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
The Pediatric Infectious Disease Journal|October 29, 2010
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccinesNancy Bermal, Leszek Szenborn, Alberto Edison, et al.
The New England Journal of Medicine|March 13, 2024
RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other OutcomesIlse Dieussaert, Joon Hyung Kim, Sabine Luik, et al.
Annals of Medicine|January 9, 2018
Maternal immunization: where are we now and how to move forward?Ivo Vojtek, Ilse Dieussaert, T Mark Doherty, et al.
The Journal of Infectious Diseases|December 22, 2023
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 StudyNerea Hermida, Murdo Ferguson, Isabel Leroux-Roels, et al.
The Pediatric Infectious Disease Journal|September 13, 2011
Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infantsMarkus Knuf, Heidemarie Pankow-Culot, Detlef Grunert, et al.
The Journal of Infectious Diseases|October 4, 2016
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum AdjuvantJoanne M Langley, Naresh Aggarwal, Azhar Toma, et al.
Nature Communications|October 17, 2022
ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calvesRineke de Jong, Norbert Stockhofe-Zurwieden, Judith Bonsing, et al.
Human Vaccines & Immunotherapeutics|October 14, 2016
Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studiesJacek Wysocki, Jerzy Brzostek, Ryszard Konior, et al.
The Pediatric Infectious Disease Journal|June 13, 2015
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized TrialsTimo Vesikari, Jan Hendrik Richardus, Johan Berglund, et al.
Human Vaccines & Immunotherapeutics|July 16, 2015
Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studiesJosé Garcia-Sicilia, Javier Arístegui, Félix Omeñaca, et al.
Pageof 4